Publications
Publications
- June 1994 (Revised March 1995)
- HBS Case Collection
Kurt Landgraf and Du Pont Merck Pharmaceutical Co. (A)
Abstract
Kurt Landgraf, newly named CEO of Du Pont Merck Pharmaceutical Co., addresses complaints of discrimination from African-American scientists in R&D during significant downsizing and dramatic changes within the pharmaceutical industry.
Keywords
Prejudice and Bias; Race Characteristics; Gender Characteristics; Diversity Characteristics; Conflict and Resolution; Pharmaceutical Industry
Citation
Gentile, Mary C., and Sarah Gant. "Kurt Landgraf and Du Pont Merck Pharmaceutical Co. (A)." Harvard Business School Case 394-202, June 1994. (Revised March 1995.)